Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app calm anxiety and protect the heart?

NCT ID NCT04895995

Symptom relief Sponsor: Boston University Charles River Campus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether a digital cognitive behavioral therapy (CBT) app called Daylight can reduce anxiety and improve health behaviors in adults who have had a heart event, such as a heart attack or stroke, and also experience significant anxiety. Participants will either use the app for several self-paced modules or join a waitlist for comparison. The study measures changes in anxiety symptoms and heart-related fears to see if this accessible approach could help fill a gap in care for people with cardiovascular disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A digital cognitive behavioral therapy (CBT) app called Daylight, delivered as self-paced modules
What this could lead to
If it works, this could offer a convenient, scalable way to reduce anxiety and support heart-healthy behaviors in people recovering from heart events.
What could go wrong
This is a small pilot study, so results may not apply broadly. The app may not be engaging enough, and it does not replace medical care for anxiety or heart disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Feb 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Experienced an acute CVD event (i.e., myocardial infarction, stroke/transient ischemic attack, cardiac arrest, unstable angina, congestive heart failure with hospitalization; exclusion of coronary heart disease, atrial fibrillation, and other arrhythmias) * Clinical levels of GAD symptoms as operationalized by a score of ≥10 on the GAD-7 * Age 18 or older. * Individuals must be in the post-acute phase of their CVD; this is operationalized as \> 2 months post an acute cardiac event. Exclusion Criteria: * Non-English speaker/literate * No access to a digital device * Severely vision impaired * Severe cognitive impairment * Pending acute surgery or with a life prognosis of fewer than 6 months * The presence \[by self-report\] of schizophrenia, psychosis, bipolar disorder, seizure disorder, or current substance use disorder other than nicotine * Initiation or change of psychotropic medication dosage within the past 4 weeks * Received CBT for anxiety in last 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder cardiovascular disorder generalized anxiety disorder Health Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Anxiety disorders Cardiovascular diseases Health behavior

Contacts and locations

Locations

  • Boston University

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.